Cargando…
Knockout of the peroxiredoxin 5 homologue PFAOP does not affect the artemisinin susceptibility of Plasmodium falciparum
Artemisinins are the current mainstay of malaria chemotherapy. Their exact mode of action is an ongoing matter of debate, and several factors have recently been reported to affect an early stage of artemisinin resistance of the most important human malaria parasite Plasmodium falciparum. Here, we id...
Autores principales: | Djuika, Carine F., Staudacher, Verena, Sanchez, Cecilia P., Lanzer, Michael, Deponte, Marcel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493673/ https://www.ncbi.nlm.nih.gov/pubmed/28667301 http://dx.doi.org/10.1038/s41598-017-04277-5 |
Ejemplares similares
-
Characterization of the glutathione‐dependent reduction of the peroxiredoxin 5 homolog PfAOP from Plasmodium falciparum
por: Schumann, Robin, et al.
Publicado: (2022) -
Prokaryotic ancestry and gene fusion of a dual localized peroxiredoxin in malaria parasites
por: Djuika, Carine F., et al.
Publicado: (2015) -
Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
por: Duffey, Maëlle, et al.
Publicado: (2018) -
Protein abundance and folding rather than the redox state of Kelch13 determine the artemisinin susceptibility of Plasmodium falciparum
por: Schumann, Robin, et al.
Publicado: (2021) -
Physiological jump in erythrocyte redox potential during Plasmodium falciparum development occurs independent of the sickle cell trait
por: Haag, Marvin, et al.
Publicado: (2022)